There are 2789 resources available
436P - Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)
Presenter: Omar Saavedra Santa Gadea
Session: ePoster Display
437P - Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
Presenter: Eric Van Cutsem
Session: ePoster Display
438P - First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study
Presenter: Bernard Asselain
Session: ePoster Display
439P - Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study
Presenter: John Strickler
Session: ePoster Display
440P - Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
Presenter: Emilie Hafliger
Session: ePoster Display
441P - A study of vemurafenib and cetuximab in combination with FOLFIRI for patients with BRAF V600E-mutated advanced colorectal cancer (NCT03727763): Preliminary results
Presenter: Zhan Wang
Session: ePoster Display
442P - A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
Presenter: Marta Español-Rego
Session: ePoster Display
443P - EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding
Presenter: Elizabeth Cartwright
Session: ePoster Display